JP2015516155A5 - - Google Patents

Download PDF

Info

Publication number
JP2015516155A5
JP2015516155A5 JP2015508975A JP2015508975A JP2015516155A5 JP 2015516155 A5 JP2015516155 A5 JP 2015516155A5 JP 2015508975 A JP2015508975 A JP 2015508975A JP 2015508975 A JP2015508975 A JP 2015508975A JP 2015516155 A5 JP2015516155 A5 JP 2015516155A5
Authority
JP
Japan
Prior art keywords
expression
cancer
gene
combination
thy1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015508975A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015516155A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/032677 external-priority patent/WO2013162776A1/en
Publication of JP2015516155A publication Critical patent/JP2015516155A/ja
Publication of JP2015516155A5 publication Critical patent/JP2015516155A5/ja
Pending legal-status Critical Current

Links

JP2015508975A 2012-04-27 2013-03-15 乳がん予後判定、プロゲステロン受容体サブタイプの予測および遺伝子発現に基づく抗プロゲスチン処置に対する応答の予測 Pending JP2015516155A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261639407P 2012-04-27 2012-04-27
US61/639,407 2012-04-27
PCT/US2013/032677 WO2013162776A1 (en) 2012-04-27 2013-03-15 Breast cancer prognosis, prediction of progesterone receptor subtype and|prediction of response to antiprogestin treatment based on gene expression

Publications (2)

Publication Number Publication Date
JP2015516155A JP2015516155A (ja) 2015-06-11
JP2015516155A5 true JP2015516155A5 (https=) 2016-05-12

Family

ID=48045769

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015508975A Pending JP2015516155A (ja) 2012-04-27 2013-03-15 乳がん予後判定、プロゲステロン受容体サブタイプの予測および遺伝子発現に基づく抗プロゲスチン処置に対する応答の予測

Country Status (14)

Country Link
US (1) US10501800B2 (https=)
EP (1) EP2841594A1 (https=)
JP (1) JP2015516155A (https=)
KR (1) KR20150028232A (https=)
AU (1) AU2013252913A1 (https=)
CA (1) CA2871590A1 (https=)
HK (1) HK1208057A1 (https=)
IL (1) IL235351A0 (https=)
MX (1) MX2014013044A (https=)
NZ (1) NZ701652A (https=)
PH (1) PH12014502410A1 (https=)
RU (1) RU2014147625A (https=)
WO (1) WO2013162776A1 (https=)
ZA (1) ZA201407853B (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2014013044A (es) 2012-04-27 2015-06-23 Univ Minnesota Pronostico de cancer de mamas, prediccion de subtipo de receptor de progesterona y prediccion de respuesta a tratamiento de antiprogestina basado en la expresion de genes.
US20140363425A1 (en) * 2013-03-13 2014-12-11 J. Dinny Graham Systems and methods for identifying cancers having activated progesterone receptors
US20150276767A1 (en) * 2014-03-12 2015-10-01 The University Of Sydney Systems and methods for identifying cancers having activated progesterone receptors
CN113559075A (zh) 2014-11-17 2021-10-29 康泰科思特生物制药公司 奥那司酮延长释放组合物和方法
AU2016326657B2 (en) 2015-09-25 2019-10-24 Context Biopharma, Inc. Methods of making onapristone intermediates
EP3389632A4 (en) 2015-12-15 2019-11-06 Context Biopharma Inc. AMORPHIC ONAPRISTON COMPOSITIONS AND METHOD FOR THE PRODUCTION THEREOF
WO2018102369A1 (en) 2016-11-30 2018-06-07 Arno Therapeutics, Inc. Methods for onapristone synthesis dehydration and deprotection
US10942183B2 (en) 2017-04-05 2021-03-09 Regents Of The University Of Minnesota Methods of detecting progesterone receptor and of detecting an expression level
EP3822368A1 (en) 2019-11-14 2021-05-19 Koninklijke Philips N.V. Assessment of pr cellular signaling pathway activity using mathematical modelling of target gene expression
EP4121964A1 (en) * 2020-03-17 2023-01-25 Regeneron Pharmaceuticals, Inc. Methods and systems for determining responders to treatment
JP7619556B2 (ja) * 2020-10-08 2025-01-22 藤倉化成株式会社 動脈病変を検出し、並びに、脳心臓血管障害、糖尿病、慢性腎臓病、又は固形癌を検出する、体液抗体バイオマーカー
US20250005743A1 (en) * 2023-06-30 2025-01-02 Mackay Memorial Hospital Method and system for identifying hormone receptor status

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6750015B2 (en) * 2000-06-28 2004-06-15 Kathryn B. Horwitz Progesterone receptor-regulated gene expression and methods related thereto
AU2001271579A1 (en) 2000-06-28 2002-01-08 University Technology Corporation Progesterone receptor-regulated gene expression and methods related thereto
MX2014013044A (es) 2012-04-27 2015-06-23 Univ Minnesota Pronostico de cancer de mamas, prediccion de subtipo de receptor de progesterona y prediccion de respuesta a tratamiento de antiprogestina basado en la expresion de genes.

Similar Documents

Publication Publication Date Title
JP2015516155A5 (https=)
RU2014147625A (ru) Прогнозирование рака молочной железы, предсказание подтипа прогестероновых рецепторов и предсказание ответа на лечение антипрогестином на основании генной экспрессии
Teixeira et al. Higher circulating expression levels of miR-221 associated with poor overall survival in renal cell carcinoma patients
JP2013500001A5 (https=)
Starnawska et al. Blood DNA methylation age is not associated with cognitive functioning in middle-aged monozygotic twins
Riveiro-Falkenbach et al. Intra-and inter-tumoral homogeneity of BRAFV600E mutations in melanoma tumors
RU2014120427A (ru) Определение микрорнк в плазме для обнаружения ранних стадий колоректального рака
JP2010539508A5 (https=)
Huerta et al. Role of p53, Bax, p21, and DNA-PKcs in radiation sensitivity of HCT-116 cells and xenografts
KR20160061424A (ko) 유방암으로부터 기원하는 골의 전이성 암의 예후 및 치료 방법
CN106148529A (zh) 与胃癌相关的LncRNA标记物及其专用检测引物、检测方法、试剂盒与应用
CN101792793B (zh) miR-182作为胶质瘤发生分子标志物的应用及其检测试剂盒
Puente et al. Novel potential predictive markers of sunitinib outcomes in long-term responders versus primary refractory patients with metastatic clear-cell renal cell carcinoma
Li et al. The prognostic value of COX-2 expression on circulating tumor cells in nasopharyngeal carcinoma: a prospective analysis
Yang et al. The diagnostic value and prospects of gene mutations in circulating tumor DNA for head and neck cancer monitoring
Fjeldheim et al. Polymorphisms in the estrogen receptor alpha gene (ESR1), daily cycling estrogen and mammographic density phenotypes.
KR102216725B1 (ko) 면역 항암 요법에 대한 치료 반응 예측 방법
CN103205423A (zh) 一种前列腺癌生物标志物miR-126-5P、诊断试剂盒及应用
CN105624271A (zh) 一种与结直肠癌相关的miRNA及其应用
Rokhzadi et al. Advancements in Emerging Molecular Approaches: Promising Diagnostic and Therapies Methods for Triple-Negative Breast Cancer (TNBC) Treatment
Wang et al. Differentially expressed gene profiles in the serum before and after the ultrasound-guided ethanol sclerotherapy in patients with ovarian endometriomas
JP5897823B2 (ja) 膀胱ガン診断用組成物及び方法
WO2014124267A1 (en) Method for diagnosis, prognosis and determination of treatment for cutaneous t-cell lymphoma
Ding et al. rs621554 single nucleotide polymorphism of DLC1 is associated with breast cancer susceptibility and prognosis
Serilmez et al. CAN LYVE-1 MOLECULE BE A DIAGNOSTIC BIOMARKER IN PATIENTS WITH ADVANCED LUNG CANCER?